Takeda Pharmaceutical Co. will get to arbitrate claims by a plaintiff that accused the company of delaying the generic ...

Takeda is taking back the home license for a phase 3-ready depression drug as part of an amendment to its multi-asset ...

USA-based Neurocrine Biosciences yesterday revealed it has amended its agreement with Japanese pharma major Takeda to develop ...

Stifel Nicolaus analyst Paul Matteis has maintained their bullish stance on NBIX stock, giving a Buy rating on January 24.Invest with ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) amended its agreement with Takeda Pharmaceutical Co Ltd (NYSE:TAK) to develop and commercialize osavampator (NBI-1065845/TAK-653). Under the amended ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.

U.S. President Donald Trump plans to impose tariffs on imported computer chips, pharmaceuticals and steel, he said on Monday, ...

The comments mark the latest in a number of trade-related threats unleashed by Trump in recent days. Trump said he plans to ...

Neurocrine (NBIX) initiated a Phase 3 registrational study to evaluate the efficacy, safety and tolerability of osavampator, an investigational ...

FILE - Scottie Scheffler gestures on the 18th green at Pebble Beach Golf Links during the third round of the AT&T Pebble ...

Buy and Sell Signals for Takeda Pharmaceutical Company Limited American Depositary Shares (each Representing 1/2 Of A Share ...

Neurocrine Biosciences Inc. (NASDAQ:NBIX) shares, currently trading at $148.19, maintained a positive outlook as Stifel ...